Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CVM150- Live PIV5-based MuV vaccine expressing the MuV (Iowa strain/2006) F and HN proteins formulated in 1x sucrose phosphate glutamate (\[SPG\]; sucrose, KH2PO4, K2HPO4 and L-glutamic acid) buffer.”In the company’s words, NCT06967181 on ClinicalTrials.gov
- Tested for
- Mumps
- Main trialPhase 1
- “The purpose of this trial is to evaluate the safety and immunogenicity of CVM150 and CVM26. The trial will enroll up to 60 healthy participants.”In the company’s words, NCT06967181 on ClinicalTrials.gov
Other drugs for Mumps
Coming up1
- Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Dec 2027 | A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026